Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on German Media Today.
Press releases published on June 10, 2025
Turning Uncertainty into Opportunity: VEXOS Opens Second Vietnam Office
EIN Presswire
·
June 10, 2025
HANOI, VIETNAM, June 10, 2025 /EINPresswire.com/ -- Vexos today announced the opening of its second office in Vietnam, located in Hanoi as part of its ongoing commitment to expand its Custom Material Solutions (CMS) business, and enhance global sourcing …
Law Office of Jason M. Hatfield, P.A. Receives AV Preeminent Rating from Martindale-Hubbell
LFN-PREMIUM-Network – Law Firm Newswire
·
June 10, 2025
Springdale, Arkansas – The Law Office of Jason M. Hatfield, P.A. has been awarded the AV Preeminent® rating by Martindale-Hubbell, the highest possible peer-review rating for legal ability, ethical standards, and professional excellence. This distinction …
LinkShadow Unveils CyberMeshX Platform: Ushering in the Next Era of Cybersecurity
EIN Presswire
·
June 10, 2025
LinkShadow unveils its groundbreaking CyberMeshX Platform, transitioning from siloed security to a comprehensive, mesh-driven cybersecurity ecosystem. ATHENS, GA, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- LinkShadow, a global leader in cutting- …
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
GlobeNewswire
·
June 10, 2025
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global …
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration
GlobeNewswire
·
June 10, 2025
Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its …